Progression Inhibitor For Disease Attributed To Abnormal Accumulation Of Liver Fat

Abstract

The present invention provides pharmaceutical compositions useful as agents for the inhibition of progression of diseases associated with abnormal accumulation of liver lipids. In particular, the pharmaceutical compositions of the present invention which comprise as an active ingredient a sodium/glucose co-transporter 2 inhibitor are highly suitable as an agent for the inhibition of progression of not only common fatty liver but also non-alcholic fatty liver disease (NAFL), non-alcholic steatohepatitis (NASH), hypernutritive fatty liver, diabetic fatty liver, alcholic fatty liver disease toxic fatty liver or the like.

1 . A pharmaceutical composition for the inhibition of progression of a disease associated with abnormal accumulation of liver lipids, which comprises as an active ingredient a sodium/glucose co-transporter 2 inhibitor.  
   
   
       2 . A pharmaceutical composition for the inhibition of progression as claimed in  claim 1  wherein the sodium/glucose co-transporter 2 inhibitor is 2-(4-methoxybenzyl)phenyl β-D-glucopyranoside or a pharmaceutically acceptable salt thereof, or a prodrug thereof.  
   
   
       3 . A pharmaceutical composition as claimed in  claim 1  which is used in combination with one or more selected from a group consisting of metformin, troglitazone, pioglitazone hydrochloride, bezafibrate and voglibose.  
   
   
       4 . A pharmaceutical composition as claimed in  claim 2  which is used in combination with one or more selected from a group consisting of metformin, troglitazone, pioglitazone hydrochloride, bezafibrate and voglibose.  
   
   
       1 . A pharmaceutical composition for the inhibition of progression of a disease associated with abnormal accumulation of liver lipids, which comprises as an active ingredient a sodium/glucose co-transporter 2 inhibitor.  
   
   
       2 . A pharmaceutical composition for the inhibition of progression as claimed in  claim 1  wherein the sodium/glucose co-transporter 2 inhibitor is 2-(4-methoxybenzyl)phenyl β-D-glucopyranoside or a pharmaceutically acceptable salt thereof, or a prodrug thereof.  
   
   
       3 . A pharmaceutical composition as claimed in  claim 1  or  2  which is used in combination with one or more selected from a group consisting of metformin, troglitazone, pioglitazone hydrochloride, bezafibrate and voglibose.